Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28616840 | 0.98 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL29089011 | 0.98 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL8975164 | 0.98 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL28261297 | 0.96 | DGKA (0.53) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL28896537 | 0.96 | DGKA (0.53) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL3917799 | 0.96 | DGKA (0.53) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL28518374 | 0.94 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| SCHEMBL28353538 | 0.94 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| Zinc Ion SCHEMBL29089010 | 0.94 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 | |
| Potassium Ion SCHEMBL28377997 | 0.94 | DGKA (0.52) | DGKACES2CES1LMNALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | GLAXO GROUP LIMITED | 2010-10-07 | — | — | US | disclosed |
| EP-2220043-A1 | CRYSTALLINE FORM OF AN ANTIMALARIAL COMPOUND | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009068623-A1 | CRYSTALLINE FORM OF AN ANTIMALARIAL COMPOUND | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| CN-1981747-A | Rapidly disintegrating methylcellulose tablets | SMITHKLINE BEECHAM CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1215833-C | Rapidly disintegrating methylcellulose tablets | SMITHKLINE BEECHAM CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-0361629-B1 | Heterocyclic compounds | WYETH JOHN & BROTHER LTD (GB) | 1994-06-15 | — | — | EP | disclosed |
| EP-0361629-A2 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | CYP3A43, G6PD, PYGL | DGKA 4587/4885CES2 3717/4885CES1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.